Request Demo
BenevolentAI taps former Bayer R&D chief to help steer the AI biotech out of choppy waters
24 Jan 2024
Phase 1Executive Change
BenevolentAI's new CEO will be tasked with successfully guiding the biotech through the clinic.
BenevolentAIs rocky for a number of the first AI-based biotechs that entered the clinic, including BenevolentAI. But a new year spells new hope and the company has a fresh captain to try and steady the ship.
That new CEO is Joerg Moeller, M.D., Ph.D., who has moved across from LEO Pharma, where he led R&D since 2021. But arguably more important are the nearly 20 years he spent at Bayer, ascending from the head of strategic development of the cardiovascular unit to chief of global R&D for the German pharmaceutical giant.
Moeller “is a well-known and respected figure within the target stakehLEO PharmaBenevolentAI,” the company said in its Jan. 24 announcement. Benevolent's chairman François NadBayerso praised Moeller as a “strong advocate of AI as a driver of discovery innovation and effectiveness.”
Ultimately, Benevolent is banking on Moeller’s ability to effectively and efficiBenevolentAIthe company through the clinic after a midstage fBenevolentt year. The biotech reported in April that its pan-Trk inhibitor, BEN-2293, didn't improve eczema severity or itching compared to placebo, prompting the company to walk away from the asset. The pivot also led Benevolent to lay off 180 employees.
The focus noBenevolent744, a PDE10-targeting inflammatory bowel disease med, which is in a phase 1 trial to treat ulcerative colitis. The company expects topline data to be ready in the first quartepan-Trk inhibitorBEN-2293eczemaitchingBenevolent
Benevolent will aBEN-8744inue to work on its inflammatory bowel diseasets with AstraZeneca and Merck KGaA, respectulcerative colitis tapped the biotech to find druggable targets for chronic kidney disease and idiopathic pulmonary fibrosis while Merck KGaA is hunting for oncology, neurology and immunology candidates.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.